PDF(Pubmed)
Abstract：
OBJECTIVE: To systematically identify and narratively synthesize the evidence surrounding liposomal delivery of gene therapy and the outcome for ovarian cancer.
METHODS: An electronic database search of the Embase, MEDLINE and Web of Science from inception until July 7, 2023, was conducted to identify primary studies that investigated the effect of liposomal delivery of gene therapy on ovarian cancer outcomes. Retrieved studies were assessed against the eligibility criteria for inclusion.
RESULTS: The search yielded 564 studies, of which 75 met the inclusion criteria. Four major types of liposomes were identified: cationic, neutral, polymer-coated, and ligand-targeted liposomes. The liposome with the most evidence involved cationic liposomes which are characterized by their positively charged phospholipids (n = 37, 49.3%). Similarly, those with neutrally charged phospholipids, such as 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine, were highly researched as well (n = 25, 33.3%). Eight areas of gene therapy research were identified, evaluating either target proteins/transcripts or molecular pathways: microRNAs, ephrin type-A receptor 2 (EphA2), interleukins, mitogen-activated protein kinase (MAPK), human-telomerase reverse transcriptase/E1A (hTERT/EA1), suicide gene, p53, and multidrug resistance mutation 1 (MDR1).
CONCLUSIONS: Liposomal delivery of gene therapy for ovarian cancer shows promise in many in vivo studies. Emerging polymer-coated and ligand-targeted liposomes have been gaining interest as they have been shown to have more stability and specificity. We found that gene therapy involving microRNAs was the most frequently studied. Overall, liposomal genetic therapy has been shown to reduce tumor size and weight and improve survivability. More research involving the delivery and targets of gene therapy for ovarian cancer may be a promising avenue to improve patient outcomes.
METHODS: An electronic database search of the Embase, MEDLINE and Web of Science from inception until July 7, 2023, was conducted to identify primary studies that investigated the effect of liposomal delivery of gene therapy on ovarian cancer outcomes. Retrieved studies were assessed against the eligibility criteria for inclusion.
RESULTS: The search yielded 564 studies, of which 75 met the inclusion criteria. Four major types of liposomes were identified: cationic, neutral, polymer-coated, and ligand-targeted liposomes. The liposome with the most evidence involved cationic liposomes which are characterized by their positively charged phospholipids (n = 37, 49.3%). Similarly, those with neutrally charged phospholipids, such as 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine, were highly researched as well (n = 25, 33.3%). Eight areas of gene therapy research were identified, evaluating either target proteins/transcripts or molecular pathways: microRNAs, ephrin type-A receptor 2 (EphA2), interleukins, mitogen-activated protein kinase (MAPK), human-telomerase reverse transcriptase/E1A (hTERT/EA1), suicide gene, p53, and multidrug resistance mutation 1 (MDR1).
CONCLUSIONS: Liposomal delivery of gene therapy for ovarian cancer shows promise in many in vivo studies. Emerging polymer-coated and ligand-targeted liposomes have been gaining interest as they have been shown to have more stability and specificity. We found that gene therapy involving microRNAs was the most frequently studied. Overall, liposomal genetic therapy has been shown to reduce tumor size and weight and improve survivability. More research involving the delivery and targets of gene therapy for ovarian cancer may be a promising avenue to improve patient outcomes.
摘要：
目的：系统鉴定和叙述性综合有关脂质体递送基因治疗和卵巢癌预后的证据。
方法：Embase的电子数据库搜索，从成立到2023年7月7日，MEDLINE和WebofScience进行了研究，以确定研究脂质体递送基因治疗对卵巢癌预后的影响的主要研究。检索的研究根据纳入的资格标准进行评估。
结果：搜索产生了564项研究，其中75人符合纳入标准。确定了四种主要类型的脂质体：阳离子，中性,聚合物涂层，和配体靶向脂质体。最有证据的脂质体涉及阳离子脂质体,其特征在于它们的带正电荷的磷脂(n=37,49.3%)。同样，那些带有中性电荷的磷脂，如1,2-二油酰基-sn-甘油-3-磷脂酰胆碱，也得到了高度的研究(n=25，33.3%)。确定了基因治疗研究的八个领域，评估靶蛋白/转录本或分子途径：microRNAs，ephrinA型受体2（EphA2），白细胞介素,丝裂原活化蛋白激酶(MAPK),人端粒酶逆转录酶/E1A（hTERT/EA1），自杀基因,p53和多药耐药突变1（MDR1）。
结论：脂质体递送基因治疗卵巢癌在许多体内研究中显示出希望。新兴的聚合物包被和配体靶向的脂质体已经获得了兴趣,因为它们已经显示出具有更高的稳定性和特异性。我们发现涉及microRNA的基因治疗是最常见的研究。总的来说,脂质体基因疗法已被证明可以减少肿瘤的大小和重量，并提高生存能力。更多的研究涉及卵巢癌基因治疗的递送和靶标可能是改善患者预后的有希望的途径。
方法：Embase的电子数据库搜索，从成立到2023年7月7日，MEDLINE和WebofScience进行了研究，以确定研究脂质体递送基因治疗对卵巢癌预后的影响的主要研究。检索的研究根据纳入的资格标准进行评估。
结果：搜索产生了564项研究，其中75人符合纳入标准。确定了四种主要类型的脂质体：阳离子，中性,聚合物涂层，和配体靶向脂质体。最有证据的脂质体涉及阳离子脂质体,其特征在于它们的带正电荷的磷脂(n=37,49.3%)。同样，那些带有中性电荷的磷脂，如1,2-二油酰基-sn-甘油-3-磷脂酰胆碱，也得到了高度的研究(n=25，33.3%)。确定了基因治疗研究的八个领域，评估靶蛋白/转录本或分子途径：microRNAs，ephrinA型受体2（EphA2），白细胞介素,丝裂原活化蛋白激酶(MAPK),人端粒酶逆转录酶/E1A（hTERT/EA1），自杀基因,p53和多药耐药突变1（MDR1）。
结论：脂质体递送基因治疗卵巢癌在许多体内研究中显示出希望。新兴的聚合物包被和配体靶向的脂质体已经获得了兴趣,因为它们已经显示出具有更高的稳定性和特异性。我们发现涉及microRNA的基因治疗是最常见的研究。总的来说,脂质体基因疗法已被证明可以减少肿瘤的大小和重量，并提高生存能力。更多的研究涉及卵巢癌基因治疗的递送和靶标可能是改善患者预后的有希望的途径。
